| AiRuiKa (camrelizumab) / HLB Bio Group |
ChiCTR2100049448: Efficacy and safety of FMT combined with carrelizumab in patients with advanced Esophagus cancer ,a multicenter Self-controlled clinical study |
|
|
| Not yet recruiting | N/A | 60 | | PD1+FMT ;PD1+ targeted agents or chemotherapy | Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital, fmt will give by company + self support for pd1 | Esophagus cancer | | | | |
NCT06235164: The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer |
|
|
| Active, not recruiting | N/A | 585 | RoW | immune checkpoint inhibitors: sintilimab, nivolumab, and camrelizumab | Fujian Medical University | Locally Advanced Gastric Cancer | 12/22 | 12/25 | | |
| Completed | N/A | 279 | RoW | Transarterial chemoembolization, TACE, Systemic treatment | Zhejiang University | Hepatocellular Carcinoma | 03/23 | 10/23 | | |
ChiCTR1900022192: Phase Ib trial for Neoadjuvant therapy with PD-1 Antibody (SHR-1210) and albumin-bound paclitaxel plus Gemcitabine on resectable/borderline resectable Pancreatic Cancer |
|
|
| Not yet recruiting | N/A | 26 | | Neoadjuvant therapy with PD-1 Antibody(SHR-1210) and albumin-bound paclitaxel plus Gemcitabine | Chinese PLA General Hospital (301 hospital); Level of the institution：, self-funding | Pancreatic cancer | | | | |
ChiCTR1900026625: Single-center, open-label clinical study for camrelizumab combined with radiation therapy for locally advanced or metastatic lung squamous cell carcinoma |
|
|
| Not yet recruiting | N/A | 32 | | radiotherapy+PD-1 | Linyi City People Hospital; Linyi City People Hospital, self-financed | Lung Cancer | | | | |
ChiCTR1900026736: A prospective, single-arm, exploratory study for Camrelizumab combined with TP chemotherapy for first-line treatment in patients with recurrent/metastatic or locally advanced inoperable oral squamous cell carcinoma |
|
|
| Not yet recruiting | N/A | 33 | | Camrelizumab+TP | Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, self-raised | oral squamous cell carcinoma | | | | |
ChiCTR1800020380: Clinical study for the efficacy and safety of shr-1210 injection combined with apatinib mesylate in the treatment of refractory grade III to IV glioma |
|
|
| Recruiting | N/A | 10 | | Radiotherapy + Apatinib + Temozolamide +SHR1210 | West China Hospital, Sichuan University; West China hospital of sichuan university, self-financing | Glioma | | | | |
NCT06323382: Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 240 | RoW | Locoregional therapy, TACE/HAIC, Bevacizumab, Atezolizumab, Tislelizumab, Toripalimab, Sintilimab, Camrelizumab | Sun Yat-sen University | Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab | 12/24 | 12/24 | | |
NCT06333561: HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 300 | RoW | Hepatic arterial infusion chemotherapy, Lenvatinib, Tislelizumab, Toripalimab, Sintilimab, Camrelizumab | Sun Yat-sen University | Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor, Hepatic Arterial Infusion Chemotherapy | 12/24 | 12/24 | | |
ChiCTR2000029806: Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19) |
|
|
| Recruiting | N/A | 120 | | Thymosin for injection 1.6 mg sc qd for 5 days ;Camrelizumab 200 mg single dose, diluted to 100 ml intravenous infusion ;Conventional treatment | Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital); Wuhan Jinyintan Hospital (Wuhan Infectious Diseases Hospital), Ministry of Science and Technology of China | Novel Coronavirus Pneumonia (COVID-19) | | | | |
ChiCTR1900026188: An Exploratory Clinical Study of Camrelizumab Combined With Stereotactic Radiotherapy for Advanced Liver Cancer With Portal Vein Tumor Thrombus |
|
|
| Recruiting | N/A | 30 | | camrelizumab combined with stereotactic radiotherapy | Nanjing General Hospital of Nanjing Military Command; Nanjing General Hospital of Nanjing Military Command, Self financing | Liver cancer | | | | |
ChiCTR2000031786: An Single-Arm Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy for Local Advanced Cholangiocarcinoma |
|
|
| Recruiting | N/A | 40 | | Simultaneous radiotherapy and chemotherapy combined with PD-1 | Shandong Institute of Cancer Prevention and Control; Shandong Institute of Cancer Prevention and Control, Partial self-expenditure | Cholangiocarcinoma | | | | |
ChiCTR2000031904: A randomized, controlled, open-label clinical study of Transcatheter Arterial Chemoembolization (TACE) combined with Camrelizumab in the treatment of advanced Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 40 | | Camrelizumab combined with TACE ;TACE | Shandong Cancer Prevention and Treatment Institute; Shandong Institute of Cancer Prevention and Control, Self-financing | Hepatocellular Carcinoma | | | | |
NCT05942768: Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite Stable Metastatic Colorectal Cancer |
|
|
| Completed | N/A | 103 | RoW | regorafenib plus anti-PD-1 antibodies, programmed cell death protein 1, immune checkpoint inhibitor | Hunan Cancer Hospital | Metastatic Colorectal Adenocarcinoma | 06/21 | 09/21 | | |
ChiCTR2100047034: A prospective clinical trial of Camrelizumab combined with Cryoablation in the treatment of advanced solid tumors |
|
|
| Recruiting | N/A | 60 | | Carrelizumab combined with cryoablation | Shandong Provincial Hospital; Shandong Provincial Hospital, self-funded | solid tumors | | | | |
ChiCTR2000034938: Single-center, exploratory clinical trial of camrelizumab combined with SOX regimen for neoadjuvant treatment of locally advanced gastric cancer |
|
|
| Recruiting | N/A | 30 | | Camrelizumab combined with SOX | The Second Affiliated Hospital of Shandong University; The Second Affiliated Hospital of Shandong University, Part at own expense | Locally advanced gastric cancer | | | | |
NCT04507750: Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer |
|
|
| Recruiting | N/A | 40 | RoW | Camrelizumab, apatinib mesylate | Qianfoshan Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Immune Checkpoint Inhibition | 08/21 | 08/22 | | |
ChiCTR1900025992: A randomized, controlled and open clinical study for TC regimen, TC regimen combined with Apatinib or TC regimen combined with SHR-1210 in the treatment of advanced and recurrent cervical cancer |
|
|
| Recruiting | N/A | 108 | | TC scheme ;TC scheme+Apatininb ;TC scheme+SHR-1210 | Shandong Institute of Cancer Prevention and Control; Shandong Institute of Cancer Prevention and Control, Partial self-expenditure | cervical carcinoma | | | | |
ChiCTR1900027427: A prospective, non-randomized, controlled trial of TACE in combination with PD-1 antibody (Camrelizumab) in the treatment of unresectable liver cancer |
|
|
| Recruiting | N/A | 130 | | TACE+Camrelizumab ;TACE | The First Affiliated Hospital of Zhejing University School of Medicine; The First Affiliated Hospital Zhejiang University, CSCO-Hengrui Cancer Research Fund | hepatocellular carcinoma | | | | |
ChiCTR2000034840: A Study of Camrelizumab in Combination With Pemetrexed and Carboplatin /Cisplatin in Subjects With Lung Adenocarcinoma After Radiofrequency Ablation |
|
|
| Recruiting | N/A | 30 | | Camrelizumab, Pemetrexed, Carboplatin /Cisplatin | Beijing Chao-Yang Hospital Affiliated to Capital Medical University; Beijing Chao-Yang Hospital Affiliated to Capital Medical University, raise independently | Lung Adenocarcinoma | | | | |
ChiCTR2000033932: Vascular intervention combined with camrelizumab for Patients with Inoperable solid tumor: a exploratory study |
|
|
| Recruiting | N/A | 30 | | Camrelizumab vascular intervention and intravenous injection | Heilongjiang General Hospital of Heilongjiang General Hospital of General Bureau of Agricultural Reclamation; Heilongjiang General Hospital of General Bureau of Agricultural Reclamation, self-raised | Solid Tumors | | | | |
NCT04366128: Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL |
|
|
| Recruiting | N/A | 60 | RoW | CAPA indution immunotherapy, Radiotherapy | Rong Tao | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | 12/21 | 12/23 | | |
ChiCTR1900025465: Efficacy and safety of carillizumab combined with apatinib and concurrent chemoradiotherapy in the treatment of advanced cervical cancer |
|
|
| Recruiting | N/A | 60 | | Carillizumab + apatinib ;apatinib ;carrillizumab | Shandong Tumor Combat Research Institute; Shandong Tumor Combat Research Institute, CSCO-HengRui Tumor Research Fund （Y-HR2018-200） | cervical cancer | | | | |
ChiCTR1900028637: Clinical study for PD-1 antibody SHR-1210 combined with apatinib in the first line treatment of advanced triple negative breast cancer |
|
|
| Not yet recruiting | N/A | 30 | | apatinib+SHR-1210 | PLA General Hospital; PLA General Hospital, self-financing | breast cancer | | | | |
ChiCTR1900023277: A single center, single arm, open clinical trial for anti-pd-1 antibody shr-1210 combined with apatinib mesylate for the treatment of advanced mucosal malignant melanoma |
|
|
| Not yet recruiting | N/A | 40 | | SHR-1210 combined with apatinib | Nanjing Drum Tower Hospital; Nanjing Drum Tower Hospital, Self-financing | advanced mucosal malignant melanoma | | | | |
CCGLC-009, NCT06194695: DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | N/A | 100 | RoW | drug eluting beads-transcatheter arterial chemoembolization, DEB-TACE, envatinib plus anti-PD(L)1 | Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer (CCGLC) | Cholangiocarcinoma Non-resectable | 12/24 | 06/25 | | |
ChiCTR1900026022: Clinical study for camrelizumab combined with apatinib neoadjuvant in the treatment of resectable advanced hepatocellular carcinoma |
|
|
| Not yet recruiting | N/A | 20 | | Camrelizumab combined with Apatinib | Nanjing Gulou Hospital; Nanjing Gulou Hospital, Self-financing | Liver cancer | | | | |
ChiCTR2100044645: A Study of Camrelizumab Combined with Paclitaxel-albumin and Platinum-based Chemotherapy in the Treatment of Neoadjuvant and Monotherapy for Locally Advanced Lung Squamous Cell Carcinoma |
|
|
| Recruiting | N/A | 36 | | Treatment of Neoadjuvant and Monotherapy with Camrelizumab+Paclitaxel-albumin+Platinum-based Chemotherapy | Beijing Chest Hospital, Capital Medical University; Beijing Chest Hospital, Capital Medical University, self-financing | Lung squamous cell carcinoma | | | | |
ChiCTR2000032906: Exploratory observational study of famitinib malate combined with carrillizumab in third-line and post-third-line treatment of colorectal cancer |
|
|
| Recruiting | N/A | 30 | | camrelizumab combined with famitinib | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Self-raised funds | Colorectal cancer | | | | |
ChiCTR2200059650: Observational clinical study of Camrelizumab combined with apatinib in the treatment of advanced gastric cancer ------ open, multicenter, observational study |
|
|
| Recruiting | N/A | 500 | | None | The First Affiliated Hospital of USTC West District; The First Affiliated Hospital of USTC West District, self-raised | gastric cancer | | | | |
ChiCTR2000032912: A controlled, open-label clinical study for the efficacy and safety of Camrelizumab combined with concurrent Chemoradiotherapy for stage IIIb-IVa cervical cancer |
|
|
| Recruiting | N/A | 60 | | Camrelizumab ;No intervention in the control group | Shandong Institute of Cancer Prevention and Control; Shandong Institute of Cancer Prevention and Control, Partial self-expenditure | Cervical carcinoma | | | | |
| Completed | N/A | 826 | RoW | TACE+ICIs, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 05/22 | 02/23 | | |
NCT06376773: Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping. |
|
|
| Completed | N/A | 234 | RoW | combination chemotherapy with Apatinib or Camrelizumab, mesenchymal, immunogenic, metabolic, classic | Fujian Medical University | Advanced Gastric Cancer, Neoadjuvant Therapy, Multi-omics Analysis | 07/23 | 11/23 | | |
ChiCTR2000033692: Clinical observation of hepatic portal vein ligation (PVL) combined with apatinib and Carrelizumab transformation in the treatment of patients with primary hepatocellular carcinoma with residual liver volume |
|
|
| Recruiting | N/A | 30 | | Carrillizumab, 200mg, intravenous infusion, D1, once every 14 days (Q2W), combined with apatinib, 250mg, orally, once a day (QD), continuously administered for 4 weeks (28 days), until the event of treatment termination specified in the protocol | The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, Self-raised | Primary hepatocellular carcinoma | | | | |
ChiCTR2000035716: A exploratory study of Camrelizumab combined with etoposide and carboplatin as the first-line treatment with extensive-stage small cell lung cancer |
|
|
| Recruiting | N/A | 30 | | Camrelizumab: 200mg, iv, 30min, q3w, 24 months EP: Etoposide: 100mg/ m2, d1-3, q3w, 4-6 cycles Carboplatin: AUC=5, d1, q3w, 4-6 cycles. | Tangshan People's Hospital; Tangshan People's Hospital, self-financing | small-cell lung cancer | | | | |
ChiCTR2000035166: A Single-Arm, Prospective Clinical Study of Camrelizumab Combined With Apatinib Mesylate in the Treatment of Relapsed Platinum-Resistant Epithelial Ovarian Cancer |
|
|
| Not yet recruiting | N/A | 40 | | camrelizumab plus apatinib mesylate | Shandong Provincial Qianfoshan Hospital; Shandong Provincial Qianfoshan Hospital, Part at own expense | Epithelial Ovarian Cancer | | | | |
CPOG-007-A, ChiCTR1900024176: SHR- 1210 combined with Paclitaxel (Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer |
|
|
| Recruiting | N/A | 20 | | SHR-1210, 200mg, D1; Paclitaxel (Albumin Bound), 125 mg/m2, D1, 8; Gemcitabine, 1000mg/m2, D1, 8; Every 21 days as a cycle. | Renji Hospital, School of Medicine, Shanghai Jiaotong University; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | pancreatic cancer | | | | |
ChiCTR2100048653: A retrospective real-world study of carrelizumab in the first-line treatment of advanced hepatocellular carcinoma |
|
|
| Not yet recruiting | N/A | 38 | | no intervention | Ningbo Second Hospital; Ningbo Second Hospital, self-funded | hepatocellular carcinoma | | | | |
NCT04639284: Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC |
|
|
| Recruiting | N/A | 200 | RoW | Anti-angiogenic agents plus anti-PD-1/PD-L1 antibodies | Shanghai Zhongshan Hospital | Hepatocellular Carcinoma | 07/22 | 07/23 | | |
NCT04741490: Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery |
|
|
| Recruiting | N/A | 20 | RoW | Camrelizumab, radiotherapy | Fuzhou General Hospital | Esophageal Squamous Cell Carcinomas | 08/22 | 08/23 | | |
NCT04471480: TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer |
|
|
| Not yet recruiting | N/A | 90 | RoW | TC/PD-1 inhibitor/anlotinib, TC/PD-1 inhibitor | Dong Wang | ESCC | 08/22 | 08/23 | | |
ChiCTR1900025072: Camrelizumab combined with Apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer: single arm exploratory study |
|
|
| Not yet recruiting | N/A | 62 | | Camrelizumab + Apatinib | Zhongshan Hospital, Xiamen University; Zhongshan Hospital, Xiamen University, Self-finance | Gastric cancer or colorectal cancer | | | | |
ChiCTR1900027573: Clinical Trial of Camrelizumab Combined with Cetuximab and Chemotherapy Drugs to treat Ras Wild Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 57 | | Camrelizumab, Cetuximab, and chemotherapeutics. ;Camrelizumab, Cetuximab and chemotherapeutics. | Shanghai East Hospital; Shanghai East Hospital, Expenditure of department | Ras wild colorectal cancer | | | | |
ChiCTR1900027610: An Umbrella Study to Explore Precision Treatment of Colorectal Cancer Based on Molecular Typing |
|
|
| Not yet recruiting | N/A | 60 | | Trastuzumab + Camrelizumab + Irinotecan ;Cetuximab + Pyrotinib + Irinotecan ;Cetuximab + MEK Inhibitor + Irinotecan ;PARP Inhibitor + Irinotecan | Shanghai East Hospital; Shanghai East Hospital, Expenditure of department | Colorectal Cancer | | | | |
ChiCTR2000037371: The real-world study of the effectiveness and safety of oral vinorelbine soft capsule rhythm chemotherapy combined with camrelizumab in the treatment of elderly locally advanced or metastatic non-small cell lung cancer who cannot tolerate platinum chemotherapy |
|
|
| Recruiting | N/A | 120 | | oral vinorelbine soft capsule rhythm chemotherapy combined with camrelizumab | Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, Research Founding | non-small cell lung cancer | | | | |
ChiCTR2000038254: An exploratory study of Camrelizumab combined with nab-paclitaxel in the treatment of platinum-resistant recurrent ovarian cancer |
|
|
| Not yet recruiting | N/A | 41 | | Camrelizumab: 200mg, iv, 30min, q2w Chemotherapy: nab-paclitaxel 80mg/m2 d1, 8, 15 iv q4w, until death or intolerable toxicity treatment | The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, Self-financing | Ovarian cancer | | | | |
ChiCTR2000038637: An exploratory study of Camrelizumab combined with chemoradiotherapy in the treatment of recurrent/metastatic gynecological cancers |
|
|
| Recruiting | N/A | 30 | | Camrelizumab combined with chemoradiotherapy | The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, self-finance | gynecological cancers | | | | |
ChiCTR2000038460: Canceled by the investigator A Clinical Study for the Efficacy and Safety of Camrelizumab combined with chemotherapy as the first-line treatment with locally advanced/metastatic (IIIB-IV) squamous non-small cell lung cancer |
|
|
| Suspended | N/A | 20 | | Camrelizumab: 200mg, iv, 30min, q3w, 24 months Paclitaxel For Injection (Albumin Bound): 260mg/ m2 iv d1; or Paclitaxel: 175mg/m2 iv d1; q3w, 4-6 cycles, Carboplatin: AUC=5-6, iVd1; or Cisplatin75mg/m2 iv d1; q3w, 4-6 cycles | Xingtai People's Hospital; Xingtai People's Hospital, self-financing | squamous non-small cell lung cancer | | | | |
NCT06031376: Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC |
|
|
| Completed | N/A | 106 | RoW | Fruquintinib, PD-1 inhibitors, anti-PD-1 antibodies, Trifluridine/Tipiracil, TAS-102, Lonsurf, S 95005, Bevacizumab, Avastin | Hunan Cancer Hospital | Metastatic Colorectal Adenocarcinoma | 10/22 | 03/23 | | |
ChiCTR2000034582: Neoadjuvant radiotherapy with or without PD-1 inhibitor (Camrelizumab) for resectable hepatocelluar carcinoma with portal vein tumor thrombus: a randomized multicenter controlled study |
|
|
| Not yet recruiting | N/A | 60 | | PD-1 combined with NeoRT ;NeoRT | Eastern Hepatobiliary Surgery Hospital; Eastern Hepatobiliary Surgery Hospital, National Natural Science Foundation of China | heopatocellular carcinoma | | | | |
ChiCTR2000037723: A prospective, randomized, double-blinded, multi-center clinical trial to evaluate the efficiency and safety of anti-PD1 antibody (Camrelizumab) combined with Paclitaxel(Albumin Bound) and Gemcitabine versus Paclitaxel(Albumin Bound) and Gemcitabine as first-line therapy in patients with metastatic pancreatic cancer |
|
|
| Not yet recruiting | N/A | 401 | | PD-1 antibody (Camrelizumab) combined with paclitaxel (albumin- binding) and gemcitabine ;Placebo combined with paclitaxel (albumin- binding) and gemcitabine | Renji Hospital, School of Medicine, Shanghai Jiaotong University; Renji Hospital, School of Medicine, Shanghai Jiaotong University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | pancreatic cancer | | | | |
ChiCTR2000040911: Clinical study of astragalus polysaccharide Injection combined with Carrelizumab and Apatinib in the treatment of lung cancer patients with qi and Yin deficiency and its mechanism of enhancing efficacy and reducing toxicity |
|
|
| Recruiting | N/A | 60 | | Astragalus Polysaccharide injection + Carrelizumab + Apatinib mesylate ;Carrelizumab + Apatinib mesylate | First Teaching Hospital of Tianjin University of Traditional Chinese Medicine; The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, self-raised funds | Lung cancer | | | | |
ChiCTR2000041097: Single-arm, exploratory phase II clinical study of sequential PD-1 antibody combined with apatinib maintenance treatment of advanced gastric cancer after SOX combined with camrelizumab plus apatinib first-line treatment |
|
|
| Recruiting | N/A | 20 | | camrelizumab plus apatinib and SOX | Shandong Cancer Prevention and Treatment Institute; Shandong Cancer Hospital, Self-financing | Advanced gastric cancer | | | | |
NCT05094167: Lactobacillus Bifidobacterium V9(Kex02)Improving the Efficacy of Carilizumab Combined With Platinum in Non-small Cell Lung Cancer Patients |
|
|
| Recruiting | N/A | 46 | RoW | V9, placebo | Jiangxi Provincial Cancer Hospital, Inner Mongolia Agricultural University | Non-small Cell Lung Cancer | 12/22 | 12/23 | | |
ChiCTR2000029771: An exploratory study on the first-line treatment of advanced head and neck squamous cell carcinoma with carillizumab combined with apatinib |
|
|
| Recruiting | N/A | 30 | | Carillizumab combined with Apatinib mesylate for injection | The First Medical Center of the PLA General Hospital; The First Medical Center of the PLA General Hospital, Jiangsu Hengrui Pharmaceutical Co. Ltd. | Head and neck squamous cell carcinoma | | | | |
ChiCTR2000040974: Hepatic arterial infusion chemotherapy (HAIC) combined with camrelizumab plus apatinib for advance Intrahepatic cholangiocarcinoma: a randomized controlled open-label trial |
|
|
| Recruiting | N/A | 40 | | HAIC+camrelizumab plus apatinib ;HAIC | Shandong Cancer Hospital; Shandong Cancer Hospital, Raise (funds/etc.) independently | Cholangiocarcinoma | | | | |
ChiCTR2100042198: Anti-PD-1 antibody camrelizumab, apatinib mesylate combined with low-fraction radiotherapy in the first-line treatment of oligometastatic hepatocellular carcinoma phase II clinical study |
|
|
| Recruiting | N/A | 30 | | Camrelizumab+apatinib | Shandong Cancer Research Institute; Shandong Cancer Research Institute, Part at own expense | hepatocellular carcinoma | | | | |
ChiCTR2100043472: A study of how Human Microbiota Transplantation affect the efficacy of PD-1 immunotherapy in patients with NSCLC. |
|
|
| Recruiting | N/A | 10 | | HMT+Camrelizumab | West China Hospital, Sichuan University; West China Hospital, Sichuan University, Clinical research incubation project fund of West China Hospital, Sichuan University | Lung Cancer | | | | |
ChiCTR2100043991: A single arm study for the effect and safety of Carilizumab combined with SABR in the treatment of Oligometastatic/oligorecurrent renal carcinoma |
|
|
| Recruiting | N/A | 30 | | RT+Immunotherapy | Peking University Third Hospital; Peking University Third Hospital, 1.Self financing; 2, Hengrui Medicine | Renal Carcinoma | | | | |
ChiCTR2100049322: An exploratory study of apatinib combined with carilizumab in the prevention of postoperative recurrence of liver cancer |
|
|
| Not yet recruiting | N/A | 60 | | None | The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, Jiangsu Hengrui Pharmaceutical Co. LTD | hepatocellular carcinoma | | | | |
NCT04487704: Camrelizumab Utilization on Patients With Advanced Liver Cancer |
|
|
| Recruiting | N/A | 1000 | RoW | camrelizumab | First Affiliated Hospital Xi'an Jiaotong University | Advanced Hepatocellular Carcinoma | 01/23 | 01/25 | | |
ChiCTR1900026641: A study for efficacy and safety of Camrelizumab combined with Famitinib Malate Capsules in the second-line treatment of advanced non-small cell lung cancer |
|
|
| Recruiting | N/A | 30 | | Camrelizumab combined with Famitinib Malate Capsules | Chinese PLA General Hospital; Chinese PLA General Hospital, Jiangsu HengRui Medicine Co., Ltd | Advanced non-small cell lung cancer | | | | |
CamPacBTC, ChiCTR2100042316: Second-line treatment of camrelizumab combined with nab-paclitaxel in advanced biliary tract cancer: an exploratory study |
|
|
| Recruiting | N/A | 63 | | camrelizumab + nab-paclitaxel | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Funds raised independently | biliary tract cancer | | | | |
ChiCTR2100044088: A single-arm, exploratory clinical study of beta-glucan combined with carrizumab and SOX regimen in the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma |
|
|
| Recruiting | N/A | 25 | | Camrelizumab | Second People's Hospital of Changzhou City; Second People's Hospital of Changzhou City, self-raised | Late gastric or gastroesophageal junction of adenocarcinoma | | | | |
ChiCTR2100042606: Lenvatinib combined with camrelizumab in the treatment of unresectable hepatocellular carcinoma: a one-arm, prospective, phase Ib clinical study |
|
|
| Recruiting | N/A | 50 | | Lenvatinib+camrelizumab | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Chen Xiaoping Technology Development Foundation | hepatocellular carcinoma | | | | |
NCT05233358: HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure |
|
|
| Not yet recruiting | N/A | 176 | NA | Hepatic Artery Infusion Chemotherapy, HAIC, Transarterial Chemoembolization, TACE, Regorafenib, second-line target drug, Immune Checkpoint Inhibitors, Camrelizumab, Sintilimab, Nivolumab, Pembrolizumab, Toripalimab | The Central Hospital of Lishui City | Hepatocellular Carcinoma | 02/23 | 02/25 | | |
ChiCTR2100043490: A single-arm, open-door, multicenter, real-world study of carrelizumab combined with apatinib and standard chemotherapy in second-line patients with advanced gastric cancer |
|
|
| Recruiting | N/A | 148 | | The combination is based on the second-line treatment regimen recommended by the guidelines Apatinib: 250mg orally, QD; Carilizumab: 200mg/ time, intravenous infusion, d1, Q3W; Efficacy and adverse reactions were evaluated every 3 cycles. | Shanxi Cancer Hospital; Shanxi Cancer Hospital, self-raised | gastric cancer | | | | |
ChiCTR2100044583: Camrelizumab combined with stereotactic radiotherapy (SBRT) in the treatment of advanced androgen resistant prostate cancer: a single-center, non-randomized, open -label, phase II study |
|
|
| Recruiting | N/A | 33 | | SBRT and Camrelizumab | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, 广东省广州市越秀区沿江西路107号 | Prostate cancer | | | | |
ChiCTR2100043652: Stereotactic body radiotherapy (SBRT) combined with camrelizumab and apatinib for primary liver cancer: a single-arm, exploratory clinical study |
|
|
| Recruiting | N/A | 47 | | Stereotactic body radiotherapy (SBRT) combined with camrelizumab and apatinib | Fujian Cancer Hospital; Fujian Cancer Hospital, Suzhou Shengdia Biomedical Co., Ltd. | primary liver cancer | | | | |
ChiCTR2000030976: A Study for Carelizumab Combined with Argon Helium Knife Cryoablation in the Treatment of Hepatocellular Carcinoma |
|
|
| Not yet recruiting | N/A | 40 | | camrelizumab | The First Hospital of Hebei Medical University; The First Hospital of Hebei Medical University, self-raise | Hepatocellular Carcinoma | | | | |
ChiCTR2200058126: II clinical study of carrelizumab, albumin paclitaxel and apatinib combined with or without Fuzi Lizhong Pill in the treatment of unresectable locally advanced/metastatic pancreatic cancer |
|
|
| Not yet recruiting | N/A | 30 | | NA | Second People's Hospital of Anhui Province; 安徽省合肥市北二环砀山路1868号, Self-raised | pancreatic cancer | | | | |
ChiCTR2000037901: Single-arm exploratory study of Camrelizumab maintenance treatment for locally advanced esophageal squamous cell carcinoma after concurrent radiotherapy and chemotherapy |
|
|
| Not yet recruiting | N/A | 20 | | Camrelizumab for maintenance treatment of locally advanced esophageal squamous cell carcinoma after concurrent radiotherapy and chemotherapy | Huai'an first people's Hospital; None, Company support and Self-raised | Eesophageal Cancer | | | | |
ChiCTR2100044629: Camrelizumab combined with hepatic arterial infusion chemotherapy for the treatment of advanced extrahepatic cholangiocarcinoma before surgery: a single-arm, prospective, open clinical study |
|
|
| Recruiting | N/A | 51 | | Camrelizumab | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Self-funded | Extrahepatic cholangiocarcinoma | | | | |
ChiCTR2100046429: Clinical study of camrelizumab combined with apatinib and SOX regimen in first-line treatment of advanced gastric cancer |
|
|
| Recruiting | N/A | 30 | | Camrelizumab + apatinib + ticgio + oxaliplatin | The Second Affiliated Hospital of Anhui Medical University; The Second Affiliated Hospital of Anhui Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd | gastric cancer | | | | |
ChiCTR2100044971: Efficacy and safety of Camrelizumab plus gemcitabine and cisplatin as first-line therapy for recurrent / refractory nasopharyngeal cancer |
|
|
| Recruiting | N/A | 33 | | camrelizumab combined with gemcitabine and cisplatin as first line therapy | Huadong Hospital affiliated to Fudan University; Huadong Hospital affiliated to Fudan University, HENGRUI MEDCINE | nasopharyngeal carcinoma | | | | |
ChiCTR2000032284: The efficacy and safety of Camrelizumab combined with Docetaxel and Nedaplatin in Neoadjuvant therapy for esophageal squamous cell carcinoma: A single-arm, exploratory, multicenter Phase II clinical study |
|
|
| Not yet recruiting | N/A | 20 | | Camrelizumab combined with Docetaxel and Nedaplatin | The Second People's Hospital of Dezhou City; The Second People's Hospital of Dezhou City, Self-raised | Esophageal cancer | | | | |
ChiCTR2000032372: Clinical study for the efficacy and safety of Camrelizumab combined with Nedaplatin and Tegafur, Gimeracil and Oteracil Porassium Capsules in adjuvant treatment of esophageal squamous cell carcinoma |
|
|
| Not yet recruiting | N/A | 30 | | Camrelizumab combined with Nedaplatin and Tegafur | The Second People's Hospital of Dezhou City; The Second People's Hospital of Dezhou City, Self-raised | Esophagus cancer | | | | |
ChiCTR2000032151: Efficacy and Safety of TACE Combined with Camrelizumab and Apatinib Mesylate in Treatment of Unresectable Hepatocellular Carcinoma |
|
|
| Not yet recruiting | N/A | 63 | | TACE combined with Apatinib mesylate and Camrelizumab | Cancer Hospital Chinese Academy of Medical Science; Cancer Hospital Chinese Academy of Medical Science, JIANGSU HENGRUI MEDICINE CO.,LTD. | Unresectable Hepatocellular Carcinoma | | | | |
ChiCTR2100046353: Neoadjuvant treatment of locally advanced resectable stage III esophageal squamous cell carcinoma with Camrelizumab combined with chemotherapy |
|
|
| Recruiting | N/A | 60 | | Camrelizumab + albumin paclitaxel + nedaplatin | Anhui Cancer Hospital; Anhui Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd | Esophageal Squamous Cell Carcinoma | | | | |
ChiCTR2100048076: TACE sequential MWA combined with carririzumab and apatinib in the treatment of hepatocellular carcinoma: a prospective, open, single-arm, single-center clinical study |
|
|
| Not yet recruiting | N/A | 40 | | Camrelizumab + apatinib+TACE sequential MWA | The First Affiliated Hospital of Bengbu Medical College; The First Affiliated Hospital of Bengbu Medical College, Jiangsu Hengrui Pharmaceutical Co., Ltd | Hepatocellular carcinoma(HCC) | | | | |
ChiCTR2100049159: Effects of high exposure to traditional Chinese medicine on the efficacy and safety of PD-1 in the treatment of hepatocellular carcinoma: Prospective, observational, one-arm study |
|
|
| Not yet recruiting | N/A | 50 | | Carrelizumab + traditional Chinese medicine exposure | The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd | HCC | | | | |
ChiCTR2200059131: Efficacy and safety of fecal microbiota transplants combined with carrelizumab in patients with camrelizumab resistant patients with esophageal squamous cell carcinoma |
|
|
| Not yet recruiting | N/A | 30 | | Fecal microbiota transplants combined with Camrelizumab | Meizhou People's Hospital; Meizhou People's Hospital, Company sponsorship + self-raised | Esophageal Squamous Cell Carcinoma | | | | |
ChiCTR2000033252: A Study of Camrelizumab Combined with Chemotherapy as Neoadjuvant Treatment in Locally Advanced ESCC |
|
|
| Recruiting | N/A | 30 | | Camrelizumab combined with Docetaxel and Carboplatin as neoadjuvant treatment | The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, Self-financing | Esophageal squamous cell carcinoma | | | | |
ChiCTR2000033353: A study on the efficacy and safety of transcather arterial infusion chemotherapy combined with camrelizumab followed embolization in the treatment of HCC |
|
|
| Recruiting | N/A | 30 | | camrelizumab | Shijiazhuang Ping'an Hospital; Shijiazhuang Ping'an Hospital, Self-financing | Hepatocellular Carcinoma | | | | |
ChiCTR2100054019: Clinical value and exploration of Apatinib combined with SHR-1210 in perioperative adjuvant treatment of retroperitoneal sarcomas |
|
|
| Recruiting | N/A | 93 | | Apatinib combined with SHR-1210( Before the surgery) ;surgery | Beijing Cancer Hospital / Peking University Cancer Hospital; Peking University Cancer Hospital, Capital Health Development of Special Funding Support | Retroperitoneal Sarcoma | | | | |
ChiCTR2000039442: Phase II clinical study of carrelizumab combined with albumin-binding paclitaxel in advanced triple negative breast cancer after first-line treatment |
|
|
| Recruiting | N/A | 40 | | carrelizumab combined with albumin-binding paclitaxel ;Conventional treatment | Jiangsu Provincial People's Hospital; Jiangsu Provincial People's Hospital, self-raised | triple negative breast cancer | | | | |
ChiCTR2000040079: A clinical study of perspective, open, single center on second-line treatment of advanced esophageal squamous cell carcinoma with Camrelizumab and SBRT, and academic study of Camrelizumab to improve radiotherapy. |
|
|
| Not yet recruiting | N/A | 18 | | Camrelizumab + Stereotactic Body Radiation Therapy | Affiliated Hospital of Nantong University; Affiliated Hospital of Nantong University, NA | esophageal squamous cell carcinoma | | | | |
ChiCTR2000040181: Camrelizumab combine with gemcitabine and apatinib in the treatment of advanced PD-L1 positive Biliary tract cancer: A Single-arm, open, exploratory clinical study |
|
|
| Not yet recruiting | N/A | 40 | | Camrelizumab ;gemcitabine | Jiangsu Provincial People's Hospital; None, NA | Biliary tract cancer | | | | |
ChiCTR2000040080: Clinical study of unresectable or metastatic carcinoma of pancreas, biliary tract and periampulle with Camrelizumab combined with low-dose apatinib |
|
|
| Recruiting | N/A | 30 | | Camrelizumab + Apatinib | AFFILIATED HOSPITAL OF JIANGNAN UNIVERSITY; AFFILIATED HOSPITAL OF JIANGNAN UNIVERSITY, NA | carcinoma of pancreas, biliary tract and periampulle | | | | |
ChiCTR2100047676: Clinical study of carrelizumab combined with apatinib and local implantation radiotherapy for the treatment of recurrent or metastatic cervical cancer |
|
|
| Not yet recruiting | N/A | 60 | | Nil | Shanxi Cancer Hospital; Shanxi Cancer Hospital, Nil | cervical cancer | | | | |
NCT06119347: Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors |
|
|
| Completed | N/A | 1581 | RoW | AntiVEGF, ICIs | First Affiliated Hospital of Wenzhou Medical University | AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs | 06/23 | 10/23 | | |
ChiCTR2100045061: Efficacy and safety of camrelizumab combined with apatinib in the treatment of locally advanced or metastatic exophthalmic malignancies: an exploratory clinical study |
|
|
| Recruiting | N/A | 75 | | Intravenous injection of camrelizumab + Oral administration of apatinib mesylate | Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, self-funded | Exophthalmic malignancies | | | | |
ChiCTR2000033761: An exploratory clinical study on the adjuvant treatment of locally advanced esophageal squamous cell carcinoma with carrizumab combined with paclitaxel and nedaplatin |
|
|
| Recruiting | N/A | 70 | | Camrelizumab combined with paclitaxel and nedaplatin | Affiliated Cancer Hospital of Harbin Medical University; Affiliated Cancer Hospital of Harbin Medical University, By oneself | Locally advanced esophageal squamous cell carcinoma | | | | |
ChiCTR2100049892: An observational study of carilizumab in the treatment of platinum-resistant/platinum-sensitive recurrent ovarian cancer |
|
|
| Not yet recruiting | N/A | 50 | | None | The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, Jiangsu Hengrui Pharmaceutical Co., Ltd | Ovarian cancer | | | | |
ChiCTR2100048144: Camrelizumab combined with preoperative chemotherapy in the treatment of locally advanced driver gene-negative non-small cell lung cancer: a single-arm, prospective and open clinical study |
|
|
| Not yet recruiting | N/A | 38 | | Camrelizumab | Anyang Tumor Hospital; Anyang Tumor Hospital, Self-funded | Non-small cell lung cancer | | | | |
ChiCTR2000039638: Study on the efficacy of Camrelizumab plus chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma |
|
|
| Recruiting | N/A | 30 | | Camrelizumab plus chemotherapy ;chemotherapy | Huashan Hospital Affiliated to Fudan University; Huashan Hospital Affiliated to Fudan University, Project funding | Esophageal squamous cell carcinoma | | | | |
NCT04889768: HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis |
|
|
| Not yet recruiting | N/A | 46 | RoW | HIPEC, anti-PD-1 antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery | Zhejiang Cancer Hospital | Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery | 07/23 | 07/25 | | |
ChiCTR2000034829: Camrelizumab Plus Apatinib Versus Chemotherapy for Initial Primary Unresectable Hepatic Carcinoma: a Randomized, Controlled, Single-Center, Phase II Study |
|
|
| Not yet recruiting | N/A | 60 | | Camrelizumab Plus Apatinib ;Fluorouracil combined with oxaliplatin chemotherapy | Shengjing Hospital Affiliated to China Medical University; Shengjing Hospital Affiliated to China Medical University, Independent project | Hepatic Carcinoma | | | | |
ChiCTR2100048911: A multicenter, self-controlled clinical study on the efficacy and safety of fecal bacteria transplantation combined with camrelizumab in patients with advanced liver cancer |
|
|
| Not yet recruiting | N/A | 50 | | pd1 combined with intestinal flora | Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital, Company sponsorship + self-raised | liver cancer | | | | |
| Recruiting | N/A | 474 | RoW | PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE | Zhongda Hospital | Hepatocellular Carcinoma | 08/23 | 08/23 | | |
